



Press Release May 2, 2017

Genovis expands its product portfolio and launches FabALACTICA™

Genovis is expanding its product portfolio and launching yet another unique enzyme for antibody analysis, FabALACTICA™. This enzyme is of particular interest to pharmaceutical companies that develop biological drugs in the growing immunotherapy segment. With the launch of FabALACTICA Genovis will have nine unique enzymes for antibody analysis in the product portfolio, as well as one product for labeling antibodies.

Development of new biological drugs in the immunotherapy segment is undergoing strong growth. New types of therapeutic antibodies place new demands on the reagents used for analysis. To meet this need Genovis is introducing FabALACTICA, a robust enzyme with specific activity affecting human IgG1 antibodies. The simplified protocol and unique specificity make FabALACTICA appropriate to use for daily controls of antibody products by Genovis' existing and growing customer base. Unlike similar enzymes on the market, FabALACTICA does not require additives, which substantially simplifies analysis and interpretation of data.

“One aspect of Genovis' success is its ability to rapidly translate customer needs into specific products and FabALACTICA is a product that our customers have requested. It is easier to use and gives better results than other products on the market, which makes it an important addition to our growing product portfolio,” says Fredrik Olsson, CEO of Genovis.

The name FabALACTICA comes from the bacteria in which it was discovered – *Streptococcus agalactiae*. Genovis has acquired the IP rights to the enzyme from Protactio AB, which is owned by Associate Professor Ulrich von Pawel-Rammingen and Christian Spoerry at Umeå University.

“New antibody formats in immunotherapy require new enzymes for analysis. FabALACTICA delivers stable results, regardless of the antibody. We believe that initially, the product will primarily be used in preclinical development, but since it is robust it is also appropriate for applications in quality control in clinical production,” says Fredrik Olsson.

The launch of FabALACTICA is Genovis' second product launch this spring. The product is being presented at the PEGS conference in Boston. Earlier in April the company launched GlyCLICK™, a new technology for labeling antibodies.

For more information about GlyCLICK™ <http://www.genovis.com/products/fabalactica/>

For more information, please contact:

Fredrik Olsson, CEO, Genovis AB

T: +46 (0)46-12 12 33

E: fredrik.olsson@genovis.com

ABOUT GENOVIS

Genovis' business concept is to apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development



and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). Genovis shares are listed on NASDAQ First North Stockholm and Penser Bank is the Company's Certified Adviser.

T: +46 (0)8-463 83 00.

This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.

This information is information that Genovis AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, by the contact person set out above, on May 2, 2017.